Compass Therapeutics Inc. (NASDAQ: CMPX) is a clinical-stage biotechnology company developing next-generation antibody therapeutics for cancer and autoimmune diseases. Its pipeline includes immune checkpoint inhibitors and T-cell engagers with enhanced potency and selectivity. Compass emphasizes modular design and multispecific formats to overcome limitations of current biologics. It provides investors early exposure to high-potential oncology innovation and differentiated biologic platforms.